Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Psyence Biomedical Ltd. - Ordinary Shares (PBM)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science. “We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program [Canadian Business Journal (Canada)]Canadian Business Journal
- Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research ProgramGlobeNewswire
- Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets [Yahoo! Finance]Yahoo! Finance
- Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic MarketsGlobeNewswire
- Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabsGlobeNewswire
PBM
Sec Filings
- 12/10/25 - Form SCHEDULE
- 11/21/25 - Form 6-K
- 11/20/25 - Form 424B3
- PBM's page on the SEC website